Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan

Figures & data

Table 1. Baseline characteristics of patients with psoriasis treated with deucravacitinib (n = 33).

Male sex, n (%)	24 (72.7)
Age (years)^a	60.0 [56.0–74.0]
Body mass index (kg/m^2)^b	22.9 ± 3.4
Disease duration (years)^a	6.0 [2.0–30.0]
Types of psoriasis, n (%)
Plaque psoriasis	21 (63.6)
Psoriatic arthritis	10 (30.3)
Erythrodermic psoriasis	2 (6.1)
Presence of scalp lesions, n (%)	28 (84.8)
Presence of nail lesions, n (%)	16 (48.5)
Presence of genital lesions, n (%)	16 (48.5)
Current smoking, n (%)	17 (51.5)
Diabetes mellitus, n (%)	1 (3.0)
Pretreatment, n (%)
Topical corticosteroid and/or vitamin D3 alone	26 (78.8)
Apremilast	3 (9.1)
Bimekizumab	1 (3.0)
Guselkumab	1 (3.0)
Tildrakizumab	2 (6.1)
Clinical indexes
Total PASI^a	13.2 [6.2–27.6]
PASI on head and neck^a	1.0 [0.35–1.8]
PASI on trunk^a	4.5 [1.1–8.4]
PASI on upper limbs^a	2.0 [0.65–5.4]
PASI on lower limbs^a	7.2 [2.0–11.8]
DLQIa	10.5 [7–25]
Pruritus, n (%)	14 (42.4)
Laboratory findings
NLRa	2.38 [1.65–3.54]
MLRa	0.29 [0.18–0.43]
PLRa	156.4 [92.3–234.3]
CRP (mg/dL)a	0.19 [0.06–0.63]

PASI: psoriasis area and severity index; DLQI: dermatology life quality index; NLR: neutrophil-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; CRP: C-reactive protein.

^a Data provided as the median [interquartile range].

^b Data provided as the mean ± standard deviation.

Figure 1. The transition of total psoriasis area and severity index (PASI) scores (a), PASI scores on head and neck (b), trunk (c), upper limbs (d), and lower limbs (e) during deucravacitinib treatment in patients with psoriasis (n = 33). Data are provided as the median [interquartile range]. *p < .05, **p < .01 versus values of week 0; ^†p < .05, ^††p < .01 versus values of week 2; ^§p < .05 versus values of week 4; ^#p < .05 versus values of week 6, assessed by Friedman’s test with Bonferroni’s post hoc test.

Table 2. The laboratory parameters at weeks 0, 4, and 16 of deucravacitinib treatment, and the comparisons between the stages (n = 33).

	Median [interquartile range]			p
	Week 0	Week 4	Week 16	Week 0 versus week 4	Week 0 versus week 16	Week 4 versus week 16
NLR	2.38 [1.65–3.54]	2.1 [1.47–2.74]	1.86 [1.44–3.09]	.24	.46	1
MLR	0.29 [0.18–0.43]	0.29 [0.16–0.41]	0.30 [0.19–0.43]	1	1	1
PLR	156.4 [92.3–234.3]	126.2 [91.0–157.2]	131.0 [94.0–165.2]	.26	.55	1
CRP (mg/dL)	0.19 [0.06–0.63]	0.23 [0.07–0.44]	0.14 [0.088–0.52]	1	.49	1

NLR: neutrophil-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; CRP: C-reactive protein.

Table 3. Correlations between percent reduction of total PASI versus those of laboratory parameters at weeks 4 or 16 of deucravacitinib treatment in patients with psoriasis (n = 33).

	Week 4		Week 16
Laboratory parameters	Rho	p	Rho	p
NLR	0.492	.0382*	0.139	.595
MLR	0.488	.0401*	0.451	.0691
PLR	0.553	.0173*	0.306	.232
CRP	0.463	.0708	0.292	.291

PASI: psoriasis area and severity index; NLR: neutrophil-to-lymphocyte ratio; MLR: monocyte-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; CRP: C-reactive protein.

Correlations between variables were examined using Spearman’s correlation coefficient.

* Statistically significant at p < .05.

Figure 2. Achievement rates of total psoriasis area and severity index (PASI) 75, PASI 90, PASI 100, absolute PASI ≤2, absolute PASI ≤1 during deucravacitinib treatment in patients with psoriasis (n = 33).

Figure 3. The transition of peak pruritus-numerical rating scale (PP-NRS) (a), and achievement rate of PP-NRS4 (b) during deucravacitinib treatment in psoriasis patients with baseline pruritus (n = 14). Data are provided as the median [interquartile range]. *p < .05 versus values of week 0, assessed by Friedman’s test with Bonferroni’s post hoc test.

Table 4. Correlations between percent reductions of PP-NRS versus those of clinical indexes at weeks 4, 8, 12, or 16 of deucravacitinib treatment in psoriasis patients with baseline pruritus (n = 14).

	Week 4		Week 8		Week 12		Week 16
	Rho	p	Rho	p	Rho	p	Rho	p
Total PASI	0.763	<.01**	0.0511	.896	0.724	.0273*	0.647	.0599
PASI on head and neck	0.135	.71	−0.186	.659	0.75	.0321*	0.624	.135
PASI on trunk	0.733	.0158*	0.685	.0893	0.759	.0476*	0.609	.199
PASI on upper limbs	0.726	.0269*	0.824	.044	0.485	.329	0.455	.365
PASI on lower limbs	0.752	.0194*	0.353	.493	0.485	.329	0.844	.0345*
DLQI	NA						0.78	.0223*

PASI: psoriasis area and severity index; DLQI: dermatology life quality index; PP-NRS: peak pruritus numerical rating scale; NA: not applicable.

Correlations between variables were examined using Spearman’s correlation coefficient.

* Statistically significant at p < .05.

** Statistically significant at p < .01.

Table 5. Treatment-emergent adverse events (TEAEs) until week 16 of deucravacitinib treatment in patients with psoriasis (n = 33).

TEAE	Patients, n (%)
All TEAEs	6 (18.2)
Serious AE	0
AE leading to discontinuation of deucravacitinib	1 (3.0)
AE leading to death	0
Individual AEs
Noninfectious stomatitis	1 (3.0)
Exacerbation of psoriatic arthritis	1 (3.0)
Pruritus	2 (6.1)
Elevation of creatinine phosphokinase	2 (6.1)

AE: adverse event.

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.